New directions for ZD1839 in the treatment of solid tumors

Seminars in Oncology

Volumn 30, Issue 1 SUPPL. 1, 2003, Pages 49-55

  Schiller, Joan H ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ESTRAMUSTINE; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEFITINIB; IRINOTECAN; MITOXANTRONE; OXALIPLATIN; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR;

EID: 0037298141     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50032     Document Type: Review

References (60)

1. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999
2. Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase, as a target for anticancer therapy. Drugs 60:15-23, 2000 (suppl 1)
3. Hanahan D, Weinherg RA: The hallmarks of cancer. Cell 100:57-70, 2000
4. Wells A: The epidermal growth factor receptor (EGFR) A new target in cancer therapy. Signal 1:4-11, 2000
5. Kim H-G, Kassis J, Souto JC, et al: EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol Histopathol 14:1175-1182, 1999
6. Ciardiello F: Epidermal growth factor receptors and cancer. Signal 1:22-24, 2000
7. Arteaga CL, Johnson DH: Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 13:491-498, 2001
8. Nicholson RI, Gee JMW, Harper ME: EGFR and cancer prognosis. Eur J Cancer 37:S9-S15, 2001 (suppl 4)
9. Mayer A, Takimoto M, Fritz E, et al: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454-2460, 1993
10. Messa C, Russo F, Caruso MG, et al: EGF, TGF-α, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 37: 285-289, 1998
11. Hemming AW, Davis NL, Kluftinger A, et al: Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 51:147-152, 1992
12. Volm M, Rittgen W, Drings P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77:663-669, 1998
13. Ohsaki Y, Tanno S, Fujita Y, et al: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7:603-607, 2000
14. Fontanini G, Vignati S, Bigini D, et al: Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 31A:178-183, 1995
15. Dickstein BM, Wosikowski K, Bates SE: Increased resistance to cytotoxic agents in ZR75B human breast cancer cells tranfected with epidermal growth factor receptor. Mol Cell Endocrinol 110:205-211, 1995
16. Klijn JGM, Berns PMJJ, Schmitz PIM, et al: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 13:3-17, 1992
17. Baselga J, Albanell J: Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep 4:317-324, 2002
18. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
19. Ferry D, Hammond L, Ramon M, et al: Intermittent oral Zd1839 (Iressa), a novel epidermal gowth factor receptor tyrosine kinase inhibitor (Egfr-Tki) shows evidence of good tolerability and activity: Final results from a phase I study. Proc Am Soc Clin Oncol 19:3a, 2000 (abstr 5E)
20. Chan KC, Knox F, Woodhurn JR, et al: EGFR tyrosine kinase inhibition decreases epithelia proliferation in DCIS of the breast, whereas c-erbB2 blockade does not. Proc Am Assoc Cancer Res 41:482, 2000 (abstr 3074)
21. Chan KC, Knox WF, Woodburn JR, et al: ZD1839 (Iressa) an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, inhibits proliferation in normal and preinvasive breast epithelia. Clin Cancer Res 5:3735s, 1999 (suppl) (abstr)
22. Chan KC, Knox WF, Dobson R, et al: Epidermal growth factor receptor tyrosine kinase inhibition by ZD1839 ('Iressa') blocks oestrogen-stimulated proliferation and progesterone receptor expression in human breast epithelium. Proc Am Assoc Cancer Res 42:802-803, 2001 (abstr 4307)
23. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyvrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
24. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002
25. Negoro S, Nakagawa K, Fukuoka M, et al: Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumors. Proc Am Soc Clin Oncol 20:324a, 2001 (abstr 1292)
26. Kris MG, Herbst R, Rischin D, et al: Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 29:72, 2000 (suppl 1) (abstr)
27. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
28. Ciardiello F, Tortora G: A novel approach in the treatment of cancer. Targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970, 2001
29. Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21:298a, 2002 (abstr 1188)
30. Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxelbased regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1166)
31. McPherson CP, Swenson KK, Kjellberg J: Quality of life in patients with prostate cancer. Semin Oncol Nurs 17:138-146, 2001
32. Held-Warmkessel J: Treatment of advanced prostate cancer. Semin Oncol Nurs 17:118-128, 2001
33. Barton J, Blackledge G, Wakeling A: Growth factors and their receptors: New targets for prostate cancer therapy. Urology 58:114-122, 2001 (suppl 2A)
34. Kondapaka BS, Reddy KB: Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: Prostate cancer. Mol Cell Endocrinol 117:53-58, 1996
35. Xie H, Turner T, Wang M-H, et al: In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis 13:407419, 1995
36. Cohen DW, Simak R, Fair WR, et al: Expression of transforming growth factor-α and the epidermal growth factor receptor in human prostate tissues. J Urol 152:2120-2124, 1994
37. Sirotnak FM, She Y, Lee F, et al: Studies with CWR22 xenograft, models in nude mice suggest that ZD 1839 ('Iressa') may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Presented at American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer, Miami Beach, FL, October 29-November 2, 2001
38. Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
39. Geller JA, Galkin AV, Mullen L, et al: Effects of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') on androgan-dependent and androgen-independent human prostate tumor xenografts: Growth inhibition and characteristics of resistant tumors. Proc Am Assoc Cancer Res 43:1003, 2002 (abstr 4971)
40. Kim H, Muller WJ: The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 253:78-87, 1999
41. Normanno N, Ciardiello F, Brandt R, et al: Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res Treat 29:11-27, 1994
42. Lenferink AEG, Simpson JF, Shawver LK, et al: Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-α bigenic mice. Proc Natl Acad Sci U S A 97:9609-9614, 2000 (abstr 55)
43. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
44. Bundred NJ, Chan K, Anderson NG: Studies of epidmal growth factor receptor inhibition in breast cancer. Endocr Relat Cancer 8:183-189, 2001
45. Chan KC, Knox WF, Gandhi A, et al: Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg 88:412-418, 2001
46. McClelland RA, Barrow D, Madden T-A, et al: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslotex). Endocrinology 142: 2776-2788, 2001
47. Normanno N, Campiglio M, De Luca A, et al: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Hemeptin) on human breast cancer cell growth. Ann Oncol 13:65-72, 2002
48. Nicholson RI, Hutcheson IR, Harper ME, et al: Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8:175-182, 2001
49. Shou J, Massarweh S, Ge M, et al: The selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ('Iressa') blocks estrogen receptor/growth factor cross-talk implicated in tamoxifen resistance in breast cancer. Proc Am Assoc Cancer Res 43:1001, 2002 (abstr 4964)
50. Kelloff GJ, Fay JR, Steele VE, et al: Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 5:657-666, 1996
51. Ciardiello F, Damiano V, Bianco R, et al: Inhibition of EGFR-tyrosine kinase by ZD1839 ('Iressa') leads to antiproliferative and antiangiogenic effects in human GEO colon cancer xenografts, in combination with paclitaxel. Proc Am Assoc Cancer Res 42:854, 2001 (abstr 4580)
52. Williams KJ, Telfer BA, Stratford IJ, et al: Combination of ZD1839 ("Iressa"), an EGFR-TKI, and radiotherapy increases antitumour efficacy in a human colon cancer xenograft model. Proc Am Assoc Cancer Res 42:715, 2001 (abstr 3840)
53. Cohen EE, Rosen F, Eng C, et al: Phase II study of ZD1839 ('Iressa') in recurrent or metastatic squamous, cell carcinoma (SCC) of the head and neck. Lung Cancer 34:S50, 2001 (suppl 1) (abstr)
54. Hong WK: Chemoprevention of lung cancer. Oncology 13:135-141, 1999 (suppl 5)
55. The EGFR family in breast cancer. Signal 2:17-21, 2001
56. Jordan VC, Morrow M: Chemoprevention of breast cancer: A model for change [editorial]. J Clin Oncol 20:1-3, 2002
57. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53:2379-2385, 1993
58. Averbuch SD: Lung cancer prevention: retinoids and the epidermal growth factor receptor-A phoenix rising [editorial]? Clin Cancer Res 8:1-3, 2002
59. Kurie JM, Shin HJ, Lee JS, et al: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2:1787-1793, 1996
60. Lonardo F, Dragnev KH, Freemantle SJ, et al: Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 8:54-60, 2002